// App-Quantinova.ai

1017 : Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).

Researchers

Presenter

  • Komal L. Jhaveri

Principal Investigators

  • Joohyuk Sohn

  • Rafael Villanueva-Vsquez

  • Aditya Bardia

  • Peter Schmid

  • Elgene Lim

  • Jaymin M. Patel

  • Jose Alejandro Perez-Fidalgo

  • Sherene Loi

  • Seock-Ah Im

  • Smita Kshirsagar

  • Mary R. Gates

  • John Bond

  • Jennifer Eng-Wong

  • Ching-Wei Chang

  • Nicholas C. Turner

  • Elena Lopez Miranda

  • Laura Garca-Estvez

  • Meritxell Bellet

Medical Centers

  • Memorial Sloan Kettering Cancer Center, New York, NY, START Madrid-CIOCC, Centro Integral Oncologico Clara Campal, HM Hospitales Sanchinarro, Madrid, Spain

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,...

  • ICO LHospitalet (Hospital Duran i Reynals), Barcelona, Spain

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Connie Johnson Breast Cancer Research Laboratory, Garvan Institute of Medical Research, St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Darlinghurst, Australia

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Seoul National University College of Medicine, Seoul, Korea

  • Genentech, Inc., South San Francisico, CA

  • Exploratory Clinical Development, Genentech Inc, South San Francisco, CA

  • The Royal Marsden Hospital, London, United Kingdom

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • GEICO & MD Anderson Cancer Center Madrid, Madrid, Spain

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Locations

  • Spain

  • United Kingdom

  • Australia

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • LHRH

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03332797

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved